How a Japanese Drugmaker Clinched Win Over Alzheimer’s
- Eisai persevered in amyloid theory after high-profile failures
- CEO apologized for taking so long to develop breakthrough
A scan of a brain of a patient affected by Alzheimer's Disease.
Source: BSIP/Universal Images Group/Getty Images
This article is for subscribers only.
(This story was originally published Sept. 29. On Thursday, the US Food and Drug Administration granted full approval for the drug, making it eligible for broader insurance coverage.)
Three decades after the presumed cause of Alzheimer’s disease was identified, a Japanese company little known outside of the pharmaceutical industry has become the first drugmaker to prove the debilitating condition can be slowed.